The multi-national study has enrolled more than 330 patients and is designed to assess the efficacy and safety of bevasiranib administered every eight or 12 weeks in preventing vision loss due to wet age-related macular degeneration (AMD).
Phillip Frost, chairman and CEO of Opko Health, said: “This first-ever Phase III trial of an agent based on RNAi technology is a milestone in the field of RNAi. With the completion of enrollment, we are one step closer to our goal of submitting a new drug application to regulatory agencies worldwide.”